Autoantibody to thioredoxin reductase in an ovarian cancer patient.
暂无分享,去创建一个
M. Hagiwara | Y. Muro | Y. Kato | Y. Ogawa | Yoshinao Muro | Yasushi Ogawa | Yoshihiro Kato | Masatoshi Hagiwara
[1] G. Powis,et al. Redox signaling and the control of cell growth and death. , 1997, Advances in pharmacology.
[2] G. Powis,et al. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. , 1996, Anticancer research.
[3] G. Powis,et al. Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. , 1996, Genomics.
[4] K. Sugimoto,et al. Clinical features of anti‐chromo antibodies associated with anti‐centromere antibodies , 1996, Clinical and experimental immunology.
[5] K. Irie,et al. A Novel Kinase Cascade Mediated by Mitogen-activated Protein Kinase Kinase 6 and MKK3* , 1996, The Journal of Biological Chemistry.
[6] Mats Andersson,et al. NK-lysin, a Disulfide-containing Effector Peptide of T-lymphocytes, Is Reduced and Inactivated by Human Thioredoxin Reductase , 1996, The Journal of Biological Chemistry.
[7] G. Powis,et al. Cloning and sequencing of a human thioredoxin reductase , 1995, FEBS letters.
[8] J. Yodoi,et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.
[9] E. Chan,et al. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. , 1995, Biochemical and biophysical research communications.
[10] R. Houghten,et al. Synthetic compound peptide simulating antigenicity of conformation-dependent autoepitope. , 1994, The Journal of biological chemistry.
[11] P. Laurent-Puig,et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.
[12] D. Thomson,et al. Analysis of the anti-p53 antibody response in cancer patients. , 1993, Cancer research.
[13] J. Minna,et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.
[14] E. Tan,et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. , 1992, The American journal of pathology.
[15] 室 慶直. The heterogeneity of anticentromere antibodies in immunoblotting analysis. , 1990 .
[16] E. Tan,et al. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. , 1989, Advances in immunology.
[17] H. Hansson,et al. Ultrastructural demonstration of thioredoxin and thioredoxin reductase in rat hepatocytes. , 1988, European journal of cell biology.
[18] H. Yamanaka,et al. Rapid Human Autoantibodies to Poly(Adenosine Diphosphate-Ribose) Polymerase , 2022 .
[19] H. Hansson,et al. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. , 1985, European journal of cell biology.
[20] C. Cordon-Cardo,et al. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer , 1985, Neurology.
[21] D. Pim,et al. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.